IMB 2013

AACC
2013 International Market Briefing


A Briefing for the Clinical Diagnostics Industry
Monday - July 29, 2013: 7:00 am - 12:00 Noon
Houston, Texas


The IMB is Organized and Developed by Scherago International

As a value-added service to Clinical Lab Expo exhibitors, AACC and Scherago International present a special briefing for exhibitors and special guests who are attending the Clinical Lab Expo. This is the 16th in a series of annual briefings to inform exhibitors of the latest developments in world markets, highlighting opportunities for small and medium-sized manufacturers.

 

Prior to the briefing (7:00 AM to 8:00 AM) there will be an opportunity to enjoy a continental breakfast and network with the speakers. For U.S. companies, members of the U.S. Department of Commerce (DoC) Healthcare Technology Team will also be available.

 

The briefing will officially begin at 8:00 AM with Boston Biomedical Consultant's Global Update of the IVD market, including highlights from areas of the most rapid growth by market and geographic segments. The remainder of the briefing will include Southeast Asia, European market update, laboratory accreditation as a marketing tool, and POC testing in emerging markets.

 

Register Now

 
Who Should Attend
 

Of the 700 executives who registered in 2012, 80% were company officers or international marketing executives. By region of residence, registration was evenly split between North America and International locations. Below is a sample of the company titles represented:

  •     Presidents/CEOs/Managing Directors
  •     Export Managers
  •     International Marketing and Sales Managers
  •     Area Managers
  •     Market Intelligence Executives
  •     Finance Executives
  •     Business Development Managers
  •     Trade Specialists
  •     Product Managers
  •     International Consultants

IMB

 

Agenda



 

7:00 am  Continental Breakfast & Networking

Herb Burklund8:00 am - Call to Order and Introductions 

Herb Burklund, President, Scherago International, USA

  

 

Robert Christenson8:05 am - Welcome and General Comments  
Robert H. Christenson, PhD, DABCC, FACB, Professor of Pathology, University of Maryland School of Medicine, President, AACC, USA

 

 

Susan Evans8:10 am -Moderator and Speaker Introductions  

 Susan Evans, VP, VP Scientific Affairs, Beckman Coulter, Past-President, AACC, USA 

 


Greg Stutman8:15 am - Global Update
Greg Stutman, Vice President, Boston Biomedical Consultants, USA 
Abstract: As BBC celebrates its 36th year providing global IVD industry/market updates, Greg's talk will feature an update on 2012 worldwide performance as compared to 2011, a forecast of the 2017 market, and the factors influencing short-term market expansion. Growth in the emerging/developing markets continues to be one of the important factors in overall market growth as more mature markets are affected by pricing, austerity measures, and growing market consolidation.

Stefano Gradi8:55 am - How THE SMALL fish swims in a sea with BIG FISHes
Stefano Gradi, Founder, IVY Diagnostics srl, Italy

Abstract: Stefano Gradi will provide a view of a small/medium-sized enterprise which reads the market and finds potentials to be filled such as those in Southeast Asia. Indonesia, Philippines, Malaysia, Thailand are examples because they have set ambitious targets and encourage growth. The Only Thing in Common is their Diversity and therefore it is crucial to understand their: leadership, governance, information systems, financing, human resources and delivery systems. Southeast Asia has emerged as a key driving force in global IVD industries because of low operating costs (example Vietnam) and growing consumer expectations. The region is also as a growing powerhouse in R&D, skilled manpower, academic medical centers and government incentives.
        
In these countries the governments have focused on infrastructure growth, along with reforms of the welfare system in response to the demands of a rapidly expanding middle class.  The benefits are expanding healthcare infrastructures and opportunities for small- and medium-sized IVD companies.


Dr. Juergen Schulze9:35 am - IVD Europe: Value of Market Intelligence in Periods of Economic Uncertainty
Dr. Juergen Schulze, President EDMA - European Diagnostic Manufacturers Association,  Belgium President & CEO EMEA, Sysmex Europe GmbH, Germany
Abstract: The economic recession in Europe (EU+EFTA countries) has affected the IVD market, in particular countries in southern Europe, such as Greece, Portugal, Spain and Italy.  According to the MIS/EDMS* reports (covering more than 85% of the market in major countries) the European market fell in the range of 3-4% in 2012 and for 2013 we expect the decrease to be 2%. Double digit declines were seen in Greece, Poland and Portugal, but also the four largest European IVD markets (Germany, France, Italy and Spain) experienced declines in 2012.  In terms of testing segments, blood glucose test strips showed the largest decrease of -9%.

Patients from different European countries have unequal access to IVDs. The money spent on IVDs per capita per annum varies from around €4 in Romania to €44 in Switzerland. This variance is a result of different levels of emphasis in individual public health programs, a lack of uniform reimbursement procedures as well as the degree of impact that the euro crisis has had on the national economy. The around €10.5 billion spent on IVDs in 2012 in Europe corresponds to €21 per capita per annum, which is only 0.8% of the total healthcare expenditure (THE).

Although the cost of IVDs only constitutes a minor part of the THE there are measures to constrain the costs further. These include a reduced number of reimbursed tests and consolidation of laboratories. Another austerity-related effect is the decreased ability of governments to pay their debts to the IVD suppliers. Late payments represent a major challenge for suppliers in countries affected the most by the recession.

For companies in the IVD market it is essential to receive good and reliable market data, especially in times of austerity. Since the beginning of the 90s, the European Diagnostic Manufacturers Association (EDMA) has market statistics programs in place (the EDMS and the MIS), developed by the industry for the industry.

*MIS - Management Information System - Monthly IVD Flash Report EDMS - European Diagnostic Manufacturer Statistics


10:15 am Break 

10:40 am - Accreditation & Market Differentiation: An IVD Marketing Greenfield
Noel Maria Adachi, Vice President, International Market Development, College of American Pathologists, USA
Abstract: Many analysts have demonstrated that in emerging markets, as incomes have grown, standards of living improve, and the population ages, the demand for health care has skyrocketed. Heart disease, diabetes, obesity and a host of ailments related to growing affluence are becoming more prevalent. Simultaneously, governments within these countries are also seeking to establish themselves on the world stage including providing high quality patient care to their population. In many of these countries, including China and India, the regulations, standards, and different parameters for how the health system should be set up, regulated and monitored are in their infancy which opens the door to global standards. While this information isn't breaking news, what has evolved is the increased focus on the clinical laboratory as a means to differentiate institutions in a sea of competing entities. Pursuit of quality and laboratory accreditation as a moniker that demonstrates higher levels of performance is an emerging trend to achieve this differentiation. The IVD industry can serve a mutually valued role in helping laboratories achieve this goal. With a focus on China and India, this presentation will outline the essential components required of the global laboratory accreditation standards, how IVD companies can help laboratories achieve and maintain accreditation, and the value delivered to the IVD industry as laboratories seek to achieve these standards.


David James11:20 am  - POC, POU, PON-How Do We Get to the Right Cost Point in Emerging Healthcare Markets?
David James, Director, Invetech, Mount Waverly, Australia
Abstract: The evolution of point of care, point of use, and point of need test systems has been a topic of expansive discussion and interest over the past 20 years. This market sector has grown dramatically in the US with one of the most referenced test being glucose monitoring for diabetics. Over the years tests for a number of diagnostic parameters have emerged from physiological indicators to infectious disease and viral febrile diseases. The models have grown from simple lateral flow strips to complex consumables that measure immunoassay and genotypes. In developing healthcare regions of the world health delivery services have lagged. Further, evolution of the infrastructure to support better healthcare is confounded by social and cultural life styles. One way to address these inherent life style challenges is a more versatile approach built around our most versatile diagnostic technology- portable test systems or Point of Care. The hallmark is fast results from minimally invasive sampling methods using affordable consumables. The challenge and topic of this discussion is the evaluation of test models and the trade-off analysis of instrument/consumable cost/value to develop these tests for emerging healthcare markets.



 

12:00 Noon - Adjourn 
Herb Burklund, President, Scherago International, USA

 

  

 

Register Now  




Sponsored by:

  

Invetech 

 

 

shel lab


Erba logo  

divider-rule
Questions?

 

If you have any questions or concerns, please contact:   

 

Herb Burklund
President

Scherago International

herbb@scherago.com  

 

Scherago logo
AACC logo   ASCLS